Anti-Human NGF Recombinant Antibody (Tanezumab) (CAT#: TAB-111)

Figure 1 ELISA assay with mNGF and hNGF coating (5 mg/ml) and serial dilutions of parental mAb aD11.

The experiments were done in duplicate.

Covaceuszach, S., Marinelli, S., Krastanova, I., Ugolini, G., Pavone, F., Lamba, D., & Cattaneo, A. (2012). Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody. PloS one, 7(3).

Figure 2 Analgesic efficacy of mAb aD11 (one dose: 2 mg/kg) in the long lasting protocol of neuropathic pain model.

MAb aD11 increased the ipsilateral/contralateral index, starting either from day 5.

Covaceuszach, S., Marinelli, S., Krastanova, I., Ugolini, G., Pavone, F., Lamba, D., & Cattaneo, A. (2012). Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody. PloS one, 7(3).

Figure 3 Hum-aD11 retains the biological activity of the parental mAb aD11.

mNGF induced differentiation of PC-12 cells.

Covaceuszach, S., Marinelli, S., Krastanova, I., Ugolini, G., Pavone, F., Lamba, D., & Cattaneo, A. (2012). Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody. PloS one, 7(3).

Figure 1 Anti-Human NGF Recombinant Antibody (TAB-111) in DB

DB analysis of TAB-111 was performed with recombinant human NGF protein.
NC: Negative control
PC: Positive control

Figure 2 Anti-Human NGF Recombinant Antibody (TAB-111) in ELISA

ELISA analysis of TAB-111 was performed by coating with recombinant human NGF Protein.